Page last updated: 2024-09-03

mk 0663 and substance p

mk 0663 has been researched along with substance p in 1 studies

Compound Research Comparison

Studies
(mk 0663)
Trials
(mk 0663)
Recent Studies (post-2010)
(mk 0663)
Studies
(substance p)
Trials
(substance p)
Recent Studies (post-2010) (substance p)
54917326517,2892772,010

Protein Interaction Comparison

ProteinTaxonomymk 0663 (IC50)substance p (IC50)
Substance-P receptorRattus norvegicus (Norway rat)0.0005
Substance-K receptorRattus norvegicus (Norway rat)0.2
Substance-K receptorHomo sapiens (human)0.2455
Substance-P receptorHomo sapiens (human)0.0011
Neuromedin-K receptorHomo sapiens (human)0.125
Substance-K receptorMesocricetus auratus (golden hamster)0.148

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Almeida, A; Baltazar, F; Castro, AG; Cruz, A; Lamas, N; Lima-Rodrigues, M; Oliveira, P; Pedrosa, J; Reis, RM; Valle-Fernandes, A; Vieira, A1

Other Studies

1 other study(ies) available for mk 0663 and substance p

ArticleYear
The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2010, Volume: 59, Issue:9

    Topics: Animals; Calcitonin Gene-Related Peptide; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Etoricoxib; Interleukin-10; Interleukin-1beta; Interleukin-6; Laryngitis; Male; Pyridines; Rats; Rats, Wistar; Substance P; Sulfones; Tumor Necrosis Factor-alpha

2010